Lv2
160 积分 2023-04-06 加入
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
1个月前
已完结
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
1个月前
已完结
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
1个月前
已完结
A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation
4个月前
已完结
A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation
4个月前
已完结
The safety, tolerability, pharmacokinetics and pharmacodynamics of an optimized dual GLP ‐1/ GIP receptor agonist ( BGM0504 ) in healthy volunteers: A dose‐escalation Phase I study
5个月前
已完结
Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes
5个月前
已关闭
Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes
5个月前
已完结
Tirzepatide for MASH with Liver Fibrosis
5个月前
已关闭
Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials
8个月前
已完结
皖公网安备34019202002308
